Paranasal Sinus And Nasal Cavity Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Paranasal Sinus And Nasal Cavity Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Malignant cells in the tissues of paranasal sinuses and nasal cavity results in paranasal sinus and nasal cavity cancer. It is rare type of cancer categorized into five stages (stage 0- stage 4) and of different types like adenocarcinoma, squamous cell carcinoma, melanoma, lymphoma, sarcoma etc. It can be metastasis in nature. Exposure to chemicals, dust, age, infections like HPV, smoking are the common etiological factors causing this cancer. Headache, runny nose, lump inside the nose, on the face, pain in eyes, vision changes are common signs and symptoms. Physical examination of nose, face, neck followed by radiographic findings, biopsy, laryngoscopy to examine the larynx and nasoscopy are done. Chemotherapy, radiation therapy and surgery to remove the cancer are the treatment options.
The Paranasal Sinus And Nasal Cavity Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Paranasal Sinus And Nasal Cavity Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Paranasal Sinus And Nasal Cavity Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Paranasal Sinus And Nasal Cavity Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 9 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Paranasal Sinus And Nasal Cavity Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Paranasal Sinus And Nasal Cavity Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Paranasal Sinus And Nasal Cavity Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AstraZeneca PlcBristol-Myers Squibb Co
Compugen Ltd
Exelixis Inc
GSK plc
Jiangsu Hengrui Medicine Co Ltd
Merck & Co Inc
QBiotics Group Ltd
Xuanzhu Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Paranasal Sinus And Nasal Cavity Cancer reports